small molecule

NUMBRINO

COCAINE HYDROCHLORIDE

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyOMNIVIUM PHARMACEUTICALS LLC

Drug detail

Brand nameNUMBRINO
Active ingredientCOCAINE HYDROCHLORIDE
Strength4%
Dosage formSOLUTION
RouteNASAL
ModalitySmall molecule
FDA approvalJanuary 2020
Marketing statusRX

Listed patents

PatentExpiresType
10973811February 2037use U-3680
10894012February 2037use U-3014
10857095February 2037use U-3014
10420760February 2037use U-2478
10413505February 2037use U-3014
10149843February 2037use U-2479
10016407February 2037use U-2329
9867815February 2037use U-2226
10933060February 2037use U-3014
11040032February 2037product
10231961February 2037product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NUMBRINO patent cliff — loss of exclusivity February 2037 | CliffBio